JPWO2019178024A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019178024A5
JPWO2019178024A5 JP2020549671A JP2020549671A JPWO2019178024A5 JP WO2019178024 A5 JPWO2019178024 A5 JP WO2019178024A5 JP 2020549671 A JP2020549671 A JP 2020549671A JP 2020549671 A JP2020549671 A JP 2020549671A JP WO2019178024 A5 JPWO2019178024 A5 JP WO2019178024A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
nanoparticles
composition according
taxan
hydrophobic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020549671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518362A (ja
JP7372252B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021751 external-priority patent/WO2019178024A1/en
Publication of JP2021518362A publication Critical patent/JP2021518362A/ja
Publication of JPWO2019178024A5 publication Critical patent/JPWO2019178024A5/ja
Application granted granted Critical
Publication of JP7372252B2 publication Critical patent/JP7372252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020549671A 2018-03-16 2019-03-12 タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍(cin)および子宮頸癌の処置のための局所療法 Active JP7372252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643861P 2018-03-16 2018-03-16
US62/643,861 2018-03-16
PCT/US2019/021751 WO2019178024A1 (en) 2018-03-16 2019-03-12 Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes

Publications (3)

Publication Number Publication Date
JP2021518362A JP2021518362A (ja) 2021-08-02
JPWO2019178024A5 true JPWO2019178024A5 (enExample) 2022-03-10
JP7372252B2 JP7372252B2 (ja) 2023-10-31

Family

ID=67906931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020549671A Active JP7372252B2 (ja) 2018-03-16 2019-03-12 タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍(cin)および子宮頸癌の処置のための局所療法

Country Status (7)

Country Link
US (2) US11497726B2 (enExample)
EP (1) EP3765035A4 (enExample)
JP (1) JP7372252B2 (enExample)
KR (1) KR20200132963A (enExample)
CN (1) CN112165949A (enExample)
CA (1) CA3092500A1 (enExample)
WO (1) WO2019178024A1 (enExample)

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PT1155689E (pt) 1993-07-19 2007-01-31 Angiotech Pharm Inc Composições anti-angiogenicas e metodos de utilização
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
ES2248847T3 (es) 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
CA2189916C (en) 1996-11-08 2001-01-16 Parkash S. Gill A new regime for paclitaxel in kaposi's sarcoma patients
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6982091B2 (en) 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
DK1023050T3 (da) 1997-06-27 2013-10-14 Abraxis Bioscience Llc Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
IN191203B (enExample) 1999-02-17 2003-10-04 Amarnath Prof Maitra
US6406722B1 (en) 1999-02-18 2002-06-18 Robert G. Gallaher Method of treating viral infections and lesions with taxane compounds
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
DK1180020T4 (da) 1999-05-27 2009-10-05 Acusphere Inc Poröse lægemiddelmatrixer og fremgangsmåder til fremstilling deraf
US6892091B1 (en) 2000-02-18 2005-05-10 Biosense, Inc. Catheter, method and apparatus for generating an electrical map of a chamber of the heart
JP2004501143A (ja) 2000-06-22 2004-01-15 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化タキサン、組成物および使用方法
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
CN1592607A (zh) 2001-10-15 2005-03-09 克里蒂泰克公司 水溶性差药物的组合物、其给药方法和治疗方法
US20080220075A1 (en) 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2479665C (en) 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
AU2003304108B2 (en) 2002-10-30 2007-03-22 Spherics, Inc. Nanoparticulate bioactive agents
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
AU2004283464B8 (en) 2003-10-15 2011-04-14 Syncore Biotechnology Co., Ltd Method of administering cationic liposomes comprising an active drug
CA2544627A1 (en) 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
FR2862540B1 (fr) 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
FR2871695B1 (fr) 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises
US7361683B2 (en) 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
US8062658B2 (en) 2004-12-14 2011-11-22 Poly-Med, Inc. Multicomponent bioactive intravaginal ring
WO2006091780A2 (en) 2005-02-24 2006-08-31 Elan Pharma International Limited Nanoparticulate formulations of docetaxel and analogues thereof
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
JP5106384B2 (ja) 2005-04-27 2012-12-26 ライデン ユニバーシティ メディカル センター Hpv誘導性上皮内腫瘍の治療方法及び治療手段
WO2006133271A2 (en) 2005-06-06 2006-12-14 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
CA2633201A1 (en) 2005-12-14 2007-06-21 Organogenesis, Inc. Skin care compositions and treatments
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
EP2077823B1 (en) 2006-10-11 2012-06-27 Crititech, Inc. Method for precipitation of small medicament particles into use containers
CA2611803C (en) 2006-11-22 2013-03-19 Bj Services Company Well treatment fluid containing viscoelastic surfactant and viscosification activator
SI2117520T1 (sl) 2006-12-14 2019-01-31 Abraxis Bioscience, Llc Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
CN101129338A (zh) 2007-08-27 2008-02-27 四川大学 超临界流体新技术微细化抗癌药物紫杉醇
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8865194B1 (en) 2007-12-20 2014-10-21 Theraplex Company, LLC Reducing tackiness and greasiness of petrolatum-like materials
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8952075B2 (en) 2008-05-22 2015-02-10 Poly-Med, Inc. Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions
CN101283976A (zh) * 2008-05-30 2008-10-15 济南基福医药科技有限公司 一种含紫杉烷类药物的抗癌缓释凝胶注射剂
US9540695B2 (en) 2008-06-17 2017-01-10 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
MX379265B (es) 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
GB2474930B (en) 2009-10-02 2012-07-04 Foamix Ltd Topical tetracycline compositions
CN102686205A (zh) 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
EP2488207A4 (en) 2009-10-13 2015-06-10 Rexahn Pharmaceuticals Inc POLYMERIC ANTIBODY RELEASE SYSTEMS
CN101829061A (zh) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
CN101843582B (zh) 2010-05-18 2011-12-21 南京工业大学 紫杉醇纳米混悬剂及其制备方法
WO2011151418A2 (en) 2010-06-02 2011-12-08 Abbott Gmbh & Co. Kg Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
EP2598114A1 (en) 2010-07-28 2013-06-05 Fondazione Irccs "Istituto Nazionale del Tumori" Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system.
US20130267490A1 (en) 2010-08-02 2013-10-10 Ranbaxy Laboratories Limited Topical pharmaceutical composition comprising nanonized silver sulfadiazine and chlorhexidine gluconate
US8563535B2 (en) 2011-03-29 2013-10-22 Kamal Mehta Combination composition comprising benzoyl peroxide and adapalene
WO2012130314A1 (en) 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
WO2012135422A2 (en) 2011-04-01 2012-10-04 University Of Florida Research Foundation, Inc. Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
US20140073615A1 (en) 2011-05-02 2014-03-13 Lipidor Ab Treatment of Psoriasis
WO2013002636A1 (en) 2011-06-27 2013-01-03 Cristal Delivery B.V. Controlled release system
SI2833905T1 (en) * 2012-04-04 2018-08-31 Halozyme, Inc. Combination therapy with hyaluronidase and tumane-directed taxane
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
JP2014114249A (ja) 2012-12-11 2014-06-26 Kanae Technos:Kk 基剤、及び皮膚外用剤
BR112015019524A8 (pt) * 2013-03-04 2019-11-19 Astrazeneca Ab combinação de um composto [i] com um taxano, método de produção de efeito anticancer, uso de um composto [i] em combinação com um taxano, composição farmacêutica e kit no tratamento de câncer
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
EP2978420A4 (en) 2013-03-28 2016-12-21 Bbs Nanotechnology Ltd STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
EA201690085A1 (ru) 2013-06-28 2016-06-30 Бинд Терапьютикс, Инк. Полимерные наночастицы доцетаксела для лечения рака
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
WO2015187194A1 (en) 2014-06-01 2015-12-10 Crititech, Inc. Use of paclitaxel particles
WO2016071365A1 (en) 2014-11-03 2016-05-12 Spherium Biomed, S.L. Topical pharmaceutical compositions of paclitaxel
CN105280869B (zh) 2015-01-07 2018-07-31 保定钰鑫电气科技有限公司 一种组合式蓄电池端子连接片
WO2016197100A1 (en) 2015-06-04 2016-12-08 Crititech, Inc. Nozzle assembly and methods for use
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
PT3439635T (pt) 2016-04-04 2021-02-11 Crititech Inc Formulações para tratamento de tumores sólidos
CN118948828A (zh) * 2017-03-15 2024-11-15 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法

Similar Documents

Publication Publication Date Title
JP2020514359A5 (enExample)
Hassan et al. Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances
JP2018531231A5 (enExample)
Zhu et al. Progress in research on paclitaxel and tumor immunotherapy
JP3953106B2 (ja) 新規なタキソイド、その製造及びそれを含有する製薬学的組成物
RU2018113280A (ru) Доставка наночастиц лекарственного средства и способы их использования
El-Ela et al. New approach in ulcer prevention and wound healing treatment using doxycycline and amoxicillin/LDH nanocomposites
Cavalcanti et al. Thiabendazole/bentonites hybrids as controlled release systems
Da Silveira et al. Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiforme
Geetha et al. Integration of in silico modeling, prediction by binding energy and experimental approach to study the amorphous chitin nanocarriers for cancer drug delivery
JP2007509978A5 (enExample)
Chowdhury et al. Green synthesis and characterization of zirconium nanoparticlefor dental implant applications
Pandey et al. Significance and applications of carbon dots in anti cancerous nanodrug conjugate development: A review
Hasani et al. Nanocontainers for drug delivery systems: A review of Halloysite nanotubes and their properties
Girigoswami et al. Versatile applications of nanosponges in biomedical field: a glimpse on SARS-CoV-2 management
Saravanabhavan et al. Graphene oxide functionalized with chitosan based nanoparticles as a carrier of siRNA in regulating Bcl-2 expression on Saos-2 & MG-63 cancer cells and its inflammatory response on bone marrow derived cells from mice
CZ66194A3 (en) Derivatives of 10-deacetooxytaxol
Himri et al. Cell and organ drug targeting: Types of drug delivery systems and advanced targeting strategies
Hasan et al. Nanoparticle-based drug delivery system for Oral Cancer: Mechanism, challenges, and therapeutic potential
JPWO2019178024A5 (enExample)
Alipour et al. Synthesis, characterization, and evaluation of Hesperetin nanocrystals for regenerative dentistry
Bekaroğlu et al. Raw and purified clay minerals for drug delivery applications
Patel et al. Sustained release of venlafaxine from venlafaxine–montmorillonite–polyvinylpyrrolidone composites
Arruda et al. Nanocarriers for delivery of taxanes: A review on physicochemical and biological aspects
Grynyuk et al. Influence of nanoscale-modified apatite-type calcium phosphates on the biofilm formation by pathogenic microorganisms